Comparison of the efficacy and safety of levofloxacin eye drops and pranoprofen gel in the treatment of bacterial conjunctivitis in the real world
Abstract
This study compared the efficacy and safety of levofloxacin eye drops and pranoprofen gel in treating bacterial conjunctivitis via a prospective randomized controlled design. A total of 200 patients with bacterial conjunctivitis were included, randomly divided into two groups (100 cases each) for 14-day corresponding drug treatment. Symptom improvement, bacterial clearance and adverse reactions were observed. Results showed that on treatment days 1 and 3, the levofloxacin group had significantly lower scores in conjunctival congestion (1.9±0.4 vs 2.1±0.5; 1.5±0.3 vs 1.7±0.4) and secretions (2.1±0.5 vs 2.3±0.6; 1.7±0.4 vs 1.9±0.5) than the pranoprofen group (all P<0.05). The bacterial clearance rate of the levofloxacin group was 85% (85/100), significantly higher than the pranoprofen group's 70% (70/100) (χ²=5.32, P<0.05). The total effective rate of the levofloxacin group was 90% (90/100), significantly higher than the pranoprofen group's 80% (80/100) (χ²=3.92, P<0.05). For safety, the adverse reaction incidence was 15% (15/100) in the levofloxacin group and 13% (13/100) in the pranoprofen group, with no significant difference (χ²=0.258, P=0.612). This study indicates levofloxacin eye drops have efficacy advantages and the two are comparable in safety, providing a valuable medication reference for clinical treatment of bacterial conjunctivitis.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 200 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.